Details

Autor(en) / Beteiligte

• Irving, Julie
• Jesson, Jenny
• Virgo, Paul
• Case, Marian
• Minto, Lynne
• Eyre, Lisa
• Noel, Nigel
• Johansson, Ulrika
• Macey, Marion
• Knotts, Linda
• Helliwell, Margaret
• Davies, Paul
• Whitby, Liam
• Barnett, David
• Hancock, Jeremy
• Goulden, Nick
• Lawson, Sarah
• on behalf of UKALL Flow MRD group and UK MRD steering group

Titel

Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting

Ist Teil von

• Haematologica (Roma), 2009-06, Vol.94 (6), p.870-874

Ort / Verlag

Pavia: Ferrata Storti Foundation

Erscheinungsjahr

2009

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• 1 Northern Institute for Cancer Research, Newcastle upon Tyne 2 Birmingham Children’s Hospital, Birmingham 3 Southmead Hospital, Bristol 4 The Royal London Hospital, London 5 Yorkhill Children’s Hospital, Glasgow 6 Sheffield Children’s Hospital, Sheffield 7 UK NEQAS for Leucocyte Immunophenotyping, Royal Hallamshire Hospital, Sheffield 8 Great Ormond Street Children’s Hospital, London, UK Correspondence: Julie Irving, Northern Institute for Cancer Research, Paul O’Gorman Building, Framlington Place, Newcastle upon Tyne, Tyne and Wear, UK, NE2 4HH. E-mail. j.a.e.irving{at}ncl.ac.uk ABSTRACT Minimal residual disease detection, used for clinical management of children with acute lymphoblastic leukemia, can be performed by molecular analysis of antigen-receptor gene rearrangements or by flow cytometric analysis of aberrant immunophenotypes. For flow minimal residual disease to be incorporated into larger national and international trials, a quality assured, standardized method is needed which can be performed in a multi-center setting. We report a four color, flow cytometric protocol established and validated by the UK acute lymphoblastic leukemia Flow minimal residual disease group. Quality assurance testing gave high inter-laboratory agreement with no values differing from a median consensus value by more than one point on a logarithmic scale. Prospective screening of B-ALL patients (n=206) showed the method was applicable to 88.3% of patients. The minimal residual disease in bone marrow aspirates was quantified and compared to molecular data. The combined risk category concordance (minimal residual disease levels above or below 0.01%) was 86% (n=134). Thus, this standardized protocol is highly reproducible between laboratories, sensitive, applicable, and shows good concordance with molecular-based analysis. Key words: childhood acute lymphoblastic leukemia, minimal residual disease, flow cytometry. Related Article Bridging the gap between the north and south of the world: the case of treatment response in childhood acute lymphoblastic leukemia Martin Stanulla, André Schrauder Haematologica 2009 94: 748-752. [Full Text] [PDF]